CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Dose Escalation Trial of Autologous Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells (WZTL-002) for Relapsed and Refractory B-cell Lymphomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04049513
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:15.758358+00:00
Published At: 2024-08-21T00:00:00+00:00
Record Updated At: 2024-08-21
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphomas Non-Hodgkin\u0027s B-Cell", "Diffuse Large B-cell Lymphoma (DLBCL)", "Primary Mediastinal B-cell Lymphoma (PMBCL)", "Transformed Follicular Lymphoma (TFL)", "Follicular Lymphoma (FL)", "Mantle Cell Lymphoma (MCL)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-08-21"
protocolSection.identificationModule.nctId: "NCT04049513"
protocolSection.identificationModule.officialTitle: "A Phase I Dose Escalation Trial of Autologous Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells (WZTL-002) for Relapsed and Refractory B-cell Lymphomas"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.